Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesGenetic & Molecular TestingSummaCare Prenatal NIPT Coverage Update | OpenPaye…
    Ask Trek AI about this page
    CurrentSummaCarePolicy N/A

    Prenatal Genetic Testing/Cell Free Genetic Testing Policy

    Customize your policy alerts

    Sign up for all summacare policy alerts

    Know when summacare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and medical necessity for sequencing-based noninvasive prenatal testing using circulating cell-free DNA to screen for fetal trisomies in commercial and Medicare members.

    Policy Summary
    PayerSummaCare
    PolicyPrenatal Genetic Testing/Cell Free Genetic Testing Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 8, 2026
    Last ReviewOct 8, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for covered sequencing-based NIPT in commercial and Medicare members.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥10 weeksMinimum gestational age
    3Covered fetal trisomies
    3Named NIPT tests
    3CPT codes listed
    Commercial and Medicare

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Plan types

    Medical Necessity Criteria

    Medical Necessity Criteria for Sequencing-Based NIPT

    Covered when ALL of the following criteria are met:

    ALL of the following

    • The pregnancy is viable.
    • The pregnancy is a single or twin gestation.
    • The pregnancy is at least 10 weeks gestation.≥ 10 weeks gestation
    • Sequencing-based non-invasive prenatal testing (NIPT) is being used to screen for fetal trisomy 13, trisomy 18, and trisomy 21.

    Covered Named NIPT Assays

    The following named tests are medically necessary when all criteria above are met:

    ONE of the following tests

    • Harmony Prenatal Test
    • MaterniT21 Plus
    • Panorama Prenatal Test for Prenatal Aneuploidy detection

    Coding and Eligibility Parameters

    CPT CodesCPT
    81420Fetal chromosomal aneuploidy (eg, trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21
    81507Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy (Harmony™ Prenatal Test)
    0494URed blood cell antigen (fetal RhD gene analysis), next-generation sequencing of circulating cell-free DNA (cfDNA) of blood in pregnant individuals known to be RhD negative, reported as positive or negative [Rh Test, Natera™]
    Minimum gestational age
    RequirementAt least 10 weeks' gestation
    Eligible pregnancy type
    Eligible pregnancyViable single or twin gestation pregnancy
    Covered fetal aneuploidies
    Covered conditionsTrisomy 13, trisomy 18, and trisomy 21

    Authorization and Denial Considerations

    Prior Authorization

    Authorization for Covered NIPT

    Authorization applies to sequencing-based non-invasive prenatal testing (NIPT) for SummaCare commercial and Medicare members. Coverage is medically necessary when the test is used to screen for fetal trisomy 13, 18, and 21 in a viable single or twin gestation at ≥ 10 weeks gestation.

    • Applies to commercial and Medicare members.
    • No NCD or LCD currently exists per CMS.
    Denial Risk

    Gestational or Pregnancy-Type Criteria Not Met

    Denial risk increases when the pregnancy does not meet the policy’s clinical criteria. Confirm documented viability, gestational age of at least 10 weeks, and a single or twin gestation before requesting authorization.

    • Pregnancy must be viable.
    • Gestational age must be ≥ 10 weeks.

    Clinical Background

    Noninvasive prenatal testing (NIPT) analyzes cell-free DNA from a maternal blood sample, including DNA of maternal and fetal origin, using sequencing to screen for fetal chromosome-number abnormalities (aneuploidies). The covered screening targets are trisomy 13, trisomy 18, and trisomy 21. Results are screening findings; a positive or abnormal result may require confirmatory testing because false-positive results can occur.

    Key Terms

    NIPT
    NIPTNoninvasive prenatal testing that purifies and sequences maternal and fetal cell-free DNA from a maternal blood sample to detect fetal aneuploidies.
    Cell-free DNA
    Cell-free DNADNA fragments circulating in maternal blood that are analyzed by sequencing-based prenatal assays to screen for fetal chromosome abnormalities.
    Aneuploidy
    AneuploidyA fetal chromosome-number abnormality, including trisomies involving chromosomes 13, 18, or 21.

    Covered NIPT Indications

    Sequencing-Based NIPT for Fetal Trisomies 13, 18, and 21

    Covered for the following indication when the listed test criteria are met:

    Sequencing-based NIPT indication

    • The pregnancy is viable and is a singleton or twin gestation.Viable single or twin gestation
    • The pregnancy is at least 10 weeks' gestation.≥ 10 weeks gestation
    • Testing screens for fetal trisomy 13, trisomy 18, and trisomy 21.
    • Named covered assays

    Eligibility Requirements

    For coverage, the pregnancy must be viable, be a single or twin gestation, and be at least 10 weeks' gestation. NIPT may be considered when there is increased risk of fetal aneuploidy, including advanced maternal age (over 35 years at delivery), abnormal ultrasound or screening results, or a family history of chromosome abnormality.

    Policy Summary
    PayerSummaCare
    PolicyPrenatal Genetic Testing/Cell Free Genetic Testing Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 8, 2026
    Last ReviewOct 8, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for covered sequencing-based NIPT in commercial and Medicare members.
    SourceLink
    On This Page
    Medical Necessity CriteriaCoding and Eligibility ParametersAuthorization and Denial ConsiderationsClinical BackgroundKey TermsCovered NIPT IndicationsEligibility Requirements
  1. Eligible pregnancy types are single or twin gestation.
  2. Denial Risk

    Named Test Criteria Not Met

    The requested assay must be one of the tests specifically identified as medically necessary when the coverage criteria are met. Requests for named tests outside these criteria may be denied.

    • Harmony Prenatal Test
    • MaterniT21 Plus
    • Panorama Prenatal Test for Prenatal Aneuploidy detection
    Harmony Prenatal Test.
  3. MaterniT21 Plus.
  4. Panorama Prenatal Test for prenatal aneuploidy detection.
  5. Increased-Risk and Other Consideration Indications

    NIPT may be considered for pregnant women with increased aneuploidy risk and for selected average- or low-risk pregnancies seeking prenatal diagnosis:

    Indications for consideration

    • Advanced maternal age, defined as older than 35 years at the time of delivery.> 35 years at delivery
    • Abnormal ultrasound results.
    • Abnormal screening test results.
    • A family history of chromosome abnormality.
    • An average- or low-risk pregnant woman is interested in pursuing prenatal diagnosis for fetal aneuploidy.